MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-31-2025
NeuroMetrix Operating Income 2011-2026 | NURO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income NeuroMetrix
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.78 M | -7.15 M | -4.74 M | -2.28 M | -2.09 M | -11.5 M | -12.3 M | -13.1 M | -15.2 M | -13.3 M | -8.77 M | -7.36 M | -10 M | -10 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.09 M | -15.2 M | -9.04 M |
Quarterly Operating Income NeuroMetrix
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.74 M | -1.83 M | -3.25 M | - | -1.96 M | -1.62 M | -1.71 M | - | -1.71 M | -1.21 M | -962 K | - | -688 K | -532 K | -60.2 K | - | -258 K | -853 K | -658 K | - | -1.41 M | -4.76 M | -3.7 M | - | -2.68 M | -3.19 M | -3.6 M | - | -3.51 M | -3.37 M | -3.31 M | - | -3.97 M | -4.18 M | -4.2 M | - | -3.36 M | -3.34 M | -3.26 M | - | -2 M | -2.62 M | -1.74 M | - | -1.6 M | -2.13 M | -2.26 M | - | -2.61 M | -2.78 M | -2.76 M | - | -2.44 M | -2.44 M | -2.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -60.2 K | -4.76 M | -2.36 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
-308 M | $ 16.61 | -0.27 % | $ 8.52 B |  USA |
 |
electroCore
ECOR
|
-13.2 M | $ 6.83 | -3.05 % | $ 57.9 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
-13.3 M | $ 9.06 | -7.08 % | $ 22 M | USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 116.47 | -0.19 % | $ 5.64 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 58.88 | 0.72 % | $ 2.96 B | USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 5.39 | -2.53 % | $ 239 M | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 116.86 | -0.31 % | $ 3.74 B | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 4.26 | - | $ 197 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 178.4 | -0.05 % | $ 9.51 B | USA |
 |
Alcon
ALC
|
580 M | $ 74.58 | -0.07 % | $ 40.4 B |  Schweiz |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 2.31 | -2.33 % | $ 106 M |  Israel |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.29 | 1.52 % | $ 23.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 25.24 | -2.21 % | $ 4.24 B | USA |
 |
The Cooper Companies
COO
|
683 M | $ 69.68 | -0.87 % | $ 13.9 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 49.01 | 0.99 % | $ 161 M | USA |
 |
ResMed
RMD
|
1 B | $ 224.23 | -0.31 % | $ 32.8 B | USA |
 |
Retractable Technologies
RVP
|
-21.2 M | $ 0.69 | -2.42 % | $ 20.7 M | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 21.32 | 1.72 % | $ 1.06 B | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.84 | -2.13 % | $ 167 M | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 115.47 | 0.37 % | $ 5.15 B | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 63.75 | 1.3 % | $ 207 M | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 18.77 | -2.59 % | $ 865 M | USA |
 |
AtriCure
ATRC
|
-9.45 M | $ 29.25 | 0.21 % | $ 1.4 B | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 258.56 | 0.67 % | $ 18.7 B | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 121.92 | -0.87 % | $ 3 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 9.49 | 0.58 % | $ 196 M | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 451.55 | -0.23 % | $ 161 B | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 109.61 | 0.41 % | $ 2.48 B | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 67.62 | -0.28 % | $ 4 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 20.31 | -11.49 % | $ 1.37 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 11.56 | -0.69 % | $ 2.31 B | USA |
 |
STERIS plc
STE
|
867 M | $ 219.29 | -0.31 % | $ 21.6 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 9.58 | -2.64 % | $ 391 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 154.54 | -0.5 % | $ 44.5 B | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 2.79 | -2.45 % | $ 29 M | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 3.02 | -1.95 % | $ 222 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 115.02 | -1.65 % | $ 6.41 M | USA |